Symmetry Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Symmetry Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,930	Closed	-$905K	–	496
2024 Q2	$905K	Sell	1,930 -943	-33%	-$409K	0.05%	176
2024 Q1	$1.2M	Hold	2,873	–	–	0.09%	147
2023 Q4	$1.18M	Hold	2,873	–	–	0.06%	148
2023 Q3	$999K	Sell	2,873 -208	-7%	-$72.7K	0.05%	180
2023 Q2	$1.08M	Hold	3,081	–	–	0.06%	183
2023 Q1	$971K	Buy	3,081 +943	+44%	+$283K	0.05%	191
2022 Q4	$617K	Hold	2,138	–	–	0.04%	277
2022 Q3	$619K	Buy	2,138 +358	+20%	+$103K	0.04%	254
2022 Q2	$502K	Buy	+1,780	New	+$476K	0.03%	317
2021 Q4	–	Sell	-1,233	Closed	-$218K	–	651
2021 Q3	$218K	Hold	1,233	–	–	0.01%	618
2021 Q2	$249K	Buy	+1,233	New	+$258K	0.02%	609
2021 Q1	–	Sell	-1,877	Closed	-$444K	–	648
2020 Q4	$444K	Sell	1,877 -79	-4%	-$18.1K	0.03%	406
2020 Q3	$532K	Sell	1,956 -91	-4%	-$25.1K	0.05%	301
2020 Q2	$594K	Buy	+2,047	New	+$555K	0.07%	121

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Symmetry Partners's VRTX Position: Q3 2024 in Review

Symmetry Partners sold out of Vertex Pharmaceuticals (VRTX) in Q3 2024, closing a stake of 1,930 shares — an estimated $905K sold.

Symmetry Partners first reported a position in VRTX in Q2 2020 and held it in 14 quarters. The position peaked at $1.2M in Q1 2024. 1,544 funds tracked by Wall St. Rank hold VRTX as of Q3 2024.

Symmetry Partners reported no remaining Vertex Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Symmetry Partners sold 1,930 Vertex Pharmaceuticals shares in Q3 2024, an estimated $905K.
Symmetry Partners first reported a position in Vertex Pharmaceuticals in Q2 2020 and held it in 14 quarters.
Symmetry Partners's Vertex Pharmaceuticals position peaked at $1.2M in Q1 2024.
1,544 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2024.

Based on Symmetry Partners's 13F filing for Q3 2024, filed 29 Oct 2024.